Silibinin down-regulates expression of secreted phospholipase a2 enzymes in cancer cells

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1723-1730

  Hagelgans, Albert ^a   Nacke, Brit ^a   Zamaraeva, Maria ^b   Siegert, Gabriele ^a   Menschikowski, Mario ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cancer cells; Secreted phospholipase A2; Signaling pathways; Silibinin

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP IB; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; PHOSPHOLIPASE A2 GROUP III; SILIBININ; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RNA ISOFORM; SECRETORY PHOSPHOLIPASE A2; SILYMARIN;

ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; INFLAMMATION; INTRACELLULAR SIGNALING; MALE; PC 3 CELL LINE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CANCER CELLS; CANCER STEM CELL; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; SECRETED PHOSPHOLIPASE A2; SIGNAL TRANSDUCTION; SIGNALING PATHWAYS; TUMOR CELL LINE;

CANCER CELLS; SECRETED PHOSPHOLIPASE A2; SIGNALING PATHWAYS; SILIBININ;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PHOSPHOLIPASES A2, SECRETORY; RNA ISOFORMS; SIGNAL TRANSDUCTION; SILYMARIN; SP1 TRANSCRIPTION FACTOR; TUMOR STEM CELL ASSAY;

EID: 84902239994     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. 2. Ann Rev Biochem 77: 495-520, 2008.
2. 2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat 79: 1-33, 2006.
3. 2 gene expression in human hepatoma cells by mediators of the acute-phase response. J Biol Chem 266: 2647-2651, 1991.
4. 2 enzymes in cancer. Biochimie 92: 601-610, 2010.
5. 2 expression in tumours: A target for therapeutic intervention? Drug Discovery Today 8: 710-716, 2003.
6. 2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers. Pathol Oncol Res 19: 839-846, 2013.
7. Bode JG, Albrecht U, Häussinger D, Heinrich PC and Schaper F: Hepatic acute phase proteins-regulation by IL6-and IL1-type cytokines involving STAT3 and its crosstalk with NFêBdependent signaling. Eur J Cell Biol 91: 496-505, 2012.
8. 2 in hepatocytes in a patient with epitheloid hemangioendothelioma of the liver. Lab Invest 74: 585-591, 1996.
9. 2 as targets for anticancer drugs. Biochem Pharmacol 74: 949-959, 2007.
10. Hackett ES, Twedt DC and Gustafson DL: Milk thistle and its derivative compounds: A review of opportunities for treatment of liver disease. J Vet Intern Med 27: 10-16, 2013.
11. Singh RP and Agarwal R: Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41: 1969-1979, 2005.
12. Deep G and Agarwal R: Targeting tumor micro environment with silibinin: Promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets 13: 486-499, 2013.
13. Giorgi VS, Peracoli MT, Peracoli JC, Witkin SS and Bannwart- Castro CF: Silibinin modulates the NFNFκBB pathway and proinflammatory cytokine production by mononuclear cells from pre-eclamptic women. J Reprod Immunol 95: 67-72, 2012.
14. Kim BR, Seo HS, Ku JM, Kim GJ, Jeon CY, Park JH, Jang BH, Park SJ, Shin YC and Ko SG: Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NFκB signaling pathway in HMC-1 human mast cells. Inflamm Res 62: 941-950, 2013.
15. Tyagi A, Agarwal C, Dwyer-Nield LD, Singh RP, Malkinson AM and Agarwal R: Silibinin modulates TNFα and IFNγ mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog 51: 832-842, 2012.
16. 2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochim Biophys Acta 1733: 157-171, 2005.
17. 2 in normal and malignant prostate cell lines: Regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia 10: 279-286, 2008.
18. 2 expressions in Jurkat leukemia cells. Neoplasia 10: 1195-1203, 2008.
19. 2 expression in human aortic smooth muscle and HepG2 hepatoma cells. FEBS Lett 577: 81-86, 2004.
20. Kandouz M, Nie D, Pidgeon GP, Krishnamoorthy S, Maddipati KR and Honn KV: Platelet-type 12-lipoxygenase activates NFκB in prostate cancer cells. Prostaglandins Other Lipid Mediat 71: 189-204, 2003.
21. Hernández M, Martín R, García-Cubillas MD, Maeso-Hernández P and Nieto ML: Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammationcancer link. Neuro Oncol 12: 1014-1023, 2010.
22. Yu JA, Kalatardi S, Dohse J, Sadaria MR, Meng X, Fullerton DA and Weyant MJ: Group IIa sPLA 2 inhibition attenuates NFκB activity and promotes apoptosis of lung cancer cells. Anticancer Res 32: 3601-3607, 2012.
23. 2. Biochim Biophys Acta 1488: 149-158, 2000.
24. Singh RP and Agarwal R: Prostate cancer chemoprevention by silibinin: Bench to bedside. Mol Carcinog 45: 436-442, 2006.
25. Raina K, Agarwal C and Agarwal R: Effect of silibinin in human colorectal cancer cells: targeting the activation of NFκB signaling. Mol Carcinog 52: 195-206, 2013.
26. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN and Oberlies NH: Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA 107: 5995-5999, 2010.
27. Zhu W, Zhang JS and Young CY: Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22: 1399-1403, 2001.
28. Zhang J, Harrison JS, Uskokovic M, Danilenko M and Studzinski GP: Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol Oncol 28: 124-132, 2010.
29. Ao C, Huo Y, Qi L, Xiong Z, Xue L and Qi Y: Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NFκB. Cell Biol Int 34: 723-730, 2010.